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Abstract
Introduction: Chemerin is a chemotactic agonist identified as a ligand for ChemR23 that is expressed on
macrophages and dendritic cells (DCs). In this study, we analyzed the expression of chemerin and ChemR23 in the
synovium of rheumatoid arthritis (RA) patients and the stimulatory effects of chemerin on fibroblast-like
synoviocytes (FLSs) from RA patients.
Methods: Chemerin and ChemR23 expression in the RA synovium was ascertained by immunohistochemistry and
Western blot analysis. Chemerin expression on cultured FLSs was analyzed by ELISA. ChemR23 expression on FLSs
was determined by immunocytochemistry and Western blot analysis. Cytokine production from FLSs was measured
by ELISA. FLS cell motility was evaluated by utilizing a scrape motility assay. We also examined the stimulating
effect of chemerin on the phosphorylation of mitogen-activated protein kinase (MAPK), p44/42 mitogen-activated
protein kinase (ERK1/2), p38MAPK, c-Jun N-terminal kinase (JNK)1/2 and Akt, as well as on the degradation of
regulator of NF-B( I Ba) in FLSs, by Western blot analysis.
Results: Chemerin was expressed on endothelial cells and synovial lining and sublining cells. ChemR23 was
expressed on macrophages, immature DCs and FLSs and a few mature DCs in the RA synovium. Chemerin and
ChemR23 were highly expressed in the RA synovium compared with osteoarthritis. Chemerin and ChemR23 were
expressed on unstimulated FLSs. TNF-a and IFN-g upregulated chemerin production. Chemerin enhanced the
production of IL-6, chemokine (C-C motif) ligand 2 and matrix metalloproteinase 3 by FLSs, as well as increasing
FLS motility. The stimulatory effects of chemerin on FLSs were mediated by activation of ERK1/2, p38MAPK and
Akt, but not by JNK1/2. Degradation of IB in FLSs was not promoted by chemerin stimulation. Inhibition of the
ERK1/2, p38MAPK and Akt signaling pathways significantly suppressed chemerin-induced IL-6 production.
Moreover, blockade of the p38MAPK and Akt pathways, but not the ERK1/2 pathway, inhibited chemerin-enhanced
cell motility.
Conclusions: The interaction of chemerin and ChemR23 may play an important role in the pathogenesis of RA
through the activation of FLSs.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by synovial hyperplasia, joint
destruction and infiltration of the synovium by immuno-
cytes, including lymphocytes, macrophages and dendritic
cells (DCs) [1-3]. In addition to these cells, fibroblast-
like synoviocytes (FLSs) play a major role in the patho-
genesis of RA [4,5] in that they produce a variety of
cytokines, chemokines and matrix-degrading enzymes
that mediate interaction with neighboring inflammatory
and endothelial cells and are responsible for the pro-
gressive inflammation in the joints and destruction of
the articular cartilage and bone [6-8].
Chemerin is the ligand protein for ChemR23, a G pro-
tein-coupled receptor expressed on macrophages, DCs
and natural killer cells (NK cells) [9-11]. Chemerin is
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ChemR23-expressing cells and acts at subnanomolar
concentrations [9,12]. Chemerin is synthesized as an
inactive precursor protein, prochemerin, which binds
ChemR23 with low affinity [9,13]. It can be rapidly con-
verted into a full ChemR23 agonist by the proteolytic
removal of the last six or seven amino acids by neutro-
phil-derived proteases (elastase and cathepsin G), mast
cell products (tryptase), proteases of the coagulation cas-
cade [14,15] and certain bacterial proteases [16] at the
inflammatory site.
Investigators in recent studies have reported that the
expression of chemerin correlates with ChemR23-posi-
tive cell recruitment in human skin inflammatory dis-
eases, such as systemic lupus erythematosus, oral
lichen planus and psoriasis [10,12,17]. Moreover, it has
been reported that chemerin and ChemR23 are
expressed by human articular chondrocytes [18] and
endothelial cells [19,20]. The interaction of chemerin
with ChemR23 is assumed to play an important role
not only in the migration of macrophages and DCs to
the sites of inflammation but also in the mediating
inflammatory signaling to articular chondrocytes and
endothelial cells. However, there is little information
on the expression and function of chemerin in the RA
synovium.
In the present study, we analyzed the expression of
chemerin and ChemR23 in the RA synovium and evalu-
ated the function of chemerin in cultured FLSs isolated
from the synovium of RA patients to explore a possible
role of chemerin and ChemR23 interaction in the patho-
genesis of RA.
Materials and methods
Specimens
Synovial tissue samples were obtained from nine RA
patients who fulfilled the American College of Rheuma-
tology diagnostic criteria for RA [21] and from four
patients with osteoarthritis (OA) who underwent total
knee joint replacement surgery. Signed consent forms
were obtained before the operations. All patients with
RA and OA were female. In RA patients, the mean age
(± SEM) was 71.0 ± 3.7 years, mean disease duration (±
SEM) was 10.75 ± 3.5 years, and their mean C-reactive
protein concentration (± SEM) was 0.33 ± 0.17 mg/dl.
Among the patients with RA, seven patients were sero-
positive for rheumatoid factor and five were positive for
anticitrullinated protein antibodies. Two of the patients
with RA were receiving prednisolone, one was being
treated with bucillamine (an analogue of D-penicilla-
mine), one was receiving methotrexate monotherapy,
one was being treated with methotrexate and etanercept
and three were was taking tocilizumab. Three patients
were receiving no medication at the surgery. The
experimental protocol was approved by the Ethics Com-
mittee of Tokyo Medical and Dental University.
Immunohistochemistry
Immunohistochemical analysis was conducted on OCT
compound-embedded sections of frozen synovial tissues.
Briefly, 8-μm-thick cryostat sections were fixed in cold
acetone (stored at -20°C) for three minutes. Endogenous
peroxidase activity was blocked by incubation in 2%
H2O2 in methanol for 15 minutes, and then nonspecific
binding was blocked with 10% normal goat serum in
PBS for 40 minutes. Serial sections were then incubated
for two hours at 4°C with 1 μg/ml rabbit anti-chemerin
pAb (affinity-purified from rabbit serum immunized
with glutathione S-transferase-chemerin (E
21-S
157) fusion
protein; provided by KAN Research Institute, Kobe,
Japan), 1 μg/ml rabbit anti-ChemR23 pAb (Acris Anti-
bodies, Herford, Germany) or normal rabbit immuno-
globulin G (IgG) (Sigma-Aldrich, St Louis, MO, USA) as
an isotype control. Antibody binding was detected using
the EnVision+ Kit (DakoCytomation, Carpinteria, CA,
USA).
For immunofluorescence double-staining with CD68,
CD1a, DC-LAMP or vimentin, and ChemR23, nonspeci-
fic binding was blocked with 1% blocking reagent
(Roche, Manheim, Germany) in PBS, and then the sec-
tions were incubated overnight at 4°C with rabbit anti-
ChemR23 pAb or normal rabbit IgG (control) at 1 μg/
ml. The samples were then incubated with Alexa Fluor
568-conjugated goat anti-rabbit IgG (4 μg/ml; Invitro-
gen, Carlsbad, CA, USA) for one hour at room tempera-
ture. Next the sections were incubated overnight with
2.35 μg/ml mouse anti-CD68 mAb (KP1; DakoCytoma-
tion), 10 μg/ml mouse anti-CD1a mAb (BL6; Immuno-
tech, Marseille, France), 10 μg/ml mouse anti-DC-
LAMP mAb (104.G4; Immunotech) or 1 μg/ml mouse
anti-vimentin mAb (V9; DakoCytomation) at 4°C. Sub-
sequently, the samples were incubated with 4 μg/ml
Alexa Fluor 488-conjugated goat anti-mouse IgG2a
(Invitrogen) or anti-mouse IgG1 (Invitrogen) for one
hour at room temperature. The slides were examined
using a Biozero Fluorescence Microscope (Keyence,
Tokyo, Japan).
For whole-mount staining, human synovial tissues
from RA patients were washed vigorously in ice-cold
PBS, then fixed and permeabilized with a BD Cytofix/
Cytoperm Kit (BD Biosciences, San Jose, CA, USA). The
whole-mount specimens of synovial tissues were then
stained with rabbit anti-ChemR23 pAb or rabbit IgG as
an isotype control, followed by secondary antibodies
conjugated with Alexa Fluor 488-conjugated goat anti-
rabbit IgG (BD Biosciences). The specimens were
further stained with Alexa Fluor 633-labeled phalloidin
(BD Biosciences). The specimens were embedded in a
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IRE2 confocal laser scanning microscope (Leica Micro-
systems, Wetzlar, Germany).
Cell cultures
Synovial tissues from RA patients were minced and
incubated with 0.5 mg/ml collagenase (Sigma-Aldrich)
for one hour at 37°C, then pressed through a metal
screen to obtain single-cell suspensions. The harvested
cells were plated in cell culture plates and incubated
with DMEM (Sigma-Aldrich) supplemented with 10%
FCS (Sigma-Aldrich). Adherent cells were maintained in
the medium as FLSs and used after five passages [22] in
the experiments that followed.
For immunofluorescence double-staining of cultured
FLSs with ChemR23 and vimentin, FLSs were incubated
on eight-well chamber slides (4 × 10
4 cells/well)
(IWAKI, Tokyo, Japan) at 37°C overnight. The adherent
cells were fixed in cold acetone for three minutes. Non-
specific binding was blocked with 10% normal goat
serum in PBS, then the cells were incubated overnight
at 4°C with rabbit anti-ChemR23 pAb or normal rabbit
IgG at 1 μg/ml. Next the cells were incubated with
Alexa Fluor 568-conjugated goat anti-rabbit IgG (4 μg/
ml) for one hour at room temperature. After that step,
the cells were incubated overnight with 1 μg/ml mouse
anti-vimentin mAb at 4°C, followed by incubation with
1 μg/ml Alexa Fluor 488-conjugated goat anti-mouse
IgG1 for one hour at room temperature. The slides
were examined using a Biozero Fluorescence Micro-
scope (Keyence).
ELISA for chemerin and inflammatory mediators
produced by cultured fibroblast-like synoviocytes
FLSs were cultured overnight in 96-well plates (2 × 10
4
cells/well) in DMEM with 10% FCS and then incubated
with or without recombinant human TNF-a (0.1, 1 or
10 ng/ml) or IFN-g (1, 10 or 100 ng/ml) (both from
R&D Systems, Minneapolis, MN, USA) at 37°C for 48
hours. The concentration of chemerin in culture super-
natant was measured with an ELISA kit (R&D Systems)
according to the instructions provided by the
manufacturer.
To determine the effects of chemerin on the produc-
tion of IL-6, chemokine (C-C motif) ligand 2 (CCL2)
and matrix metalloproteinase 3 (MMP-3) by FLSs, the
cells were cultured separately overnight in 96-well plates
(4 × 10
4 cells/well), then incubated with or without
recombinant bioactive human chemerin (2, 10 or 50
nM; R&D Systems) in FCS-free DMEM at 37°C for 24
and 48 hours. The protein levels of IL-6, CCL2 and
MMP-3 in the supernatant were assessed using ELISA
kits (R&D Systems) according to the manufacturer’s
instructions. To block the signaling pathway through
p44/42 mitogen-activated protein kinase (ERK1/2), p38
mitogen-activated protein kinase (p38MAPK) or Akt,
FLSs (4 × 10
4 cells/well) were pretreated with specific
inhibitors, including a mitogen-activated protein kinase
kinase (MEK) inhibitor (10 μM PD98059; Calbiochem,
Merck KgaA, Germany), a p38MAPK inhibitor (10 μM
SB203580; Calbiochem) or phosphoinositide 3-kinase
(PI3K) inhibitor (10 μM LY294002; Cell Signaling Tech-
nology, Danvers, MA, USA) for 30 minutes before sti-
mulation with 50 nM chemerin. To confirm the lack of
a significant amount of endotoxin in the stimulation
procedure, FLSs were incubated with 50 μg/ml poly-
myxin B in addition to 50 nM chemerin.
Scrape motility assay
RA FLSs were plated at a density of 1 × 10
5 cells/ml in
12-well plates (22.1-mm diameter) in DMEM with 10%
FCS. After overnight incubation, the tip of a plastic pip-
ette was drawn across the center of the well to produce
a scraped area [23]. The culture wells were washed
twice with PBS, and free cells were removed. Then the
cells were pretreated with or without pertussis toxin
(PTX) (0.5 μg/ml), PD98059 (10 μM), SB203580 (10
μM) or LY294002 (10 μM) for 30 minutes, followed by
i n c u b a t i o nw i t h2o r1 0n Mo fc h e m e r i na n dC C L 2i n
FCS-free medium. Immediately after scraping (zero
hours) as well as after 24-hour incubation, the process
of two-dimensional FLS migration into the cell-free area
at the center of the well was photographed with a
Nikon TE2000U inverted microscope (Nikon Instru-
ments, Tokyo, Japan) and printed. Cells that migrated
into the scraped area after 24 hours were counted by an
observer blinded to the study design. The fold increase
in the cells was calculated (number of cells with che-
merin with or without signal inhibitor per number of
cells without treatment).
Western blot analysis
Synovial tissues from patients with RA and OA were
lysed with radioimmunoprecipitation assay (RIPA) buf-
fer (Millipore, Temecula, CA, USA) containing pro-
tease inhibitor (Roche) and phosphatase inhibitor
cocktail (Sigma-Aldrich) for 30 minutes at 4°C. RA
FLSs (3 × 10
5 cells/well) were cultured overnight in
60-mm dishes in DMEM with 10% FCS, then the med-
ium was replaced with FCS-free DMEM. This step was
followed by incubation with or without recombinant
human TNF-a (10 ng/ml), IFN-g (100 ng/ml), trans-
forming growth factor-b1( T G F - b1; 1 ng/ml), IL-1b (5
n g / m l )o rI L - 6( 2 0n g / m l )( a l lf r o mR & DS y s t e m s )a t
37°C for 24 hours. After incubation, cells were col-
lected and lysed with the RIPA buffer containing pro-
tease inhibitor and phosphatase inhibitor cocktail for
30 minutes at 4°C.
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of SDS sample buffer and separated on a 10% SDS-poly-
acrylamide gel (ATTO, Tokyo, Japan). Proteins were
then electrotransferred onto a polyvinylidene fluoride
microporous membrane (Millipore) in a semidry system.
The membrane was blocked with 5% skim milk for one
hour at room temperature, then the immunoblots were
incubated overnight with rabbit anti-chemerin pAb (1:1,
000 dilution; Phoenix Pharmaceuticals, Burlingame, CA,
USA) or rabbit anti-ChemR23 pAb (1:500 dilution;
Abcam, Cambridge, UK) in Can Get Signal Immunor-
eaction Enhancer Solution (Toyobo Co, Ltd, Tokyo,
Japan) at 4°C. Peroxidase-conjugated goat anti-rabbit
IgG pAb (GE Healthcare, Birmingham, UK) was used as
the secondary antibody.
To detect phosphorylated and total ERK1/2, p38MAPK,
c-Jun N-terminal kinase (JNK)1/2 or Akt, cells were incu-
bated in a medium supplemented with 10 nM human
recombinant chemerin prior to lysis for 5, 15 or 30 min-
utes. A total of 7.5 μg of protein was boiled in the presence
of SDS sample buffer and separated on 10% SDS-polyacry-
lamide gel. After blotting, the membranes were blocked
with Block Ace blocking solution (Snow Brand Milk Pro-
ducts Co, Ltd, Tokyo, Japan) for one hour at room tem-
perature, then the immunoblots were incubated overnight
with rabbit anti-phospho-ERK1/2 pAb (1:1, 000 dilution),
rabbit anti-pan-ERK1/2 pAb (1:1, 000 dilution), rabbit anti-
phospho-p38MAPK pAb (1:1, 000 dilution), mouse anti-
pan-p38MAPK mAb (1:1, 000 dilution) (all from Cell Sig-
naling Technology), mouse anti-phospho-JNK mAb (1:300
dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
rabbit anti-pan-JNK pAb (1:1, 000 dilution), rabbit anti-
phospho-Akt pAb (1:2, 000 dilution) or rabbit anti-pan-Akt
pAb (1:1, 000 dilution) (all from Cell Signaling Technology)
in Tris-buffered saline (TBS) containing 0.1% Tween 20 at
4°C. To detect the expression of the regulator of NF-B,
(IBa), and b-actin, the immunoblots were incubated over-
night with rabbit anti-IBa pAb (1:1, 000 dilution; Santa
Cruz Biotechnology) at 4°C or with mouse anti-b-actin
mAb (1:5, 000 dilution; Sigma-Aldrich) for one hour at
room temperature in TBS containing 0.1% Tween 20. Per-
oxidase-conjugated goat anti-rabbit IgG pAb (GE Health-
care), rabbit anti-mouse IgG pAb (SouthernBiotech,
Birmingham, AL, USA), goat anti-mouse IgG pAb (Pro-
mega, Madison, WI, USA) or donkey anti-rabbit IgG pAb
(GE Healthcare) was used as the secondary Ab. ECL Plus
detection reagent and the ImageQuant LAS 4000 Mini Bio-
molecular Imager (both from GE Healthcare) were used in
conjunction with MultiGauge software (Fujifilm, Tokyo,
Japan) to detect and quantitate the bands.
Statistical analysis
Data are presented as means ± SEM. Student’s t-tests
were applied to compare two groups, and one-way ana-
lysis of variance and Dunnett’sm u l t i p l ec o m p a r i s o n
t e s t sw e r eu s e dt oc o m p a r et h r e eo rm o r eg r o u p s .P <
0.05 was considered statistically significant.
Results
Expression of chemerin and ChemR23 in the rheumatoid
arthritis synovium
Strong immunohistochemical staining for chemerin was
noted on endothelial cells and synovial lining and sub-
lining cells in the RA synovium (Figure 1A). In contrast,
chemerin expression in the OA synovium was minimal
(Figure 1B).
Widespread immunostaining for ChemR23 was noted
in all RA samples, with dense staining observed on the
sublining cells (Figure 2A). On the other hand, staining
in OA samples was much weaker (Figure 2B). Double-
staining analysis showed the presence of ChemR23
immunoreactivity on most of the CD68
+ macrophages
(Figures 2C through 2E), on CD1a
+ immature DCs
[24,25] (Figures 2F through 2H) and on a few of DC-
LAMP
+ mature DCs [26] (Figures 2I through 2K). Inter-
estingly, ChemR23 was also expressed on vimentin
+
FLSs (Figures 2L through 2N). Furthermore, we per-
formed whole-mount immunostaining of synovial tissues
with anti-ChemR23 pAb. The expression of ChemR23
w a so b s e r v e di ni n f i l t r a t e dc ells in the tissue (Figure
Figure 1 Expression of chemerin in rheumatoid arthritis and osteoarthritis synovial tissue samples. Chemerin expression in synovial
tissue samples obtained from five RA patients (A) and three OA patients (B) examined by immunohistochemistry. All sections were
counterstained with hematoxylin. OA = osteoarthritis; RA = rheumatoid arthritis.
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Page 4 of 14Figure 2 Expression of ChemR23 in rheumatoid arthritis and osteoarthritis synovial tissue samples. ChemR23 expression in synovial
tissue samples examined by immunohistochemistry that were obtained from five rheumatoid arthritis (RA) patients (A) and three osteoarthritis
(OA) patients (B). All sections were counterstained with hematoxylin. Sections of RA synovial tissues were also double-stained with CD68, CD1a,
DC-LAMP or vimentin, and ChemR23 and were analyzed by fluorescence microscopy as follows: (C) CD68, (D) ChemR23, (E) merged image of
(C) and (D), (F) CD1a, (G) ChemR23, (H) merged image of (F) and (G), (I) DC-LAMP, (J) ChemR23, (K) merged image of (I) and (J), (L) vimentin,
(M) ChemR23 and (N) merged image of (L) and (M). Arrows indicate double-positive cells. Original magnification ×100 in (A) and (B) and ×400
in (C) through (N). Whole-mount specimens obtained from RA patients were stained with anti-ChemR23 pAb (green) or phalloidin (blue) and
then analyzed by confocal laser-scanning microscopy. (O) x-y view of synovial tissue sectioning. x-z image (P) and y-z image (Q) of synovial
tissue sectioning are displayed below and to the right of the x-y view in (O). Scale bars = 80 μm. White straight line boxes indicate identical cell
in each direction (O-Q). Dashed line connects the boxes.
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an isotype-matched IgG control of irrelevant specificity
(data not shown). In addition, the x-z and y-z sectioning
images obtained by confocal microscopic analysis indi-
cated that ChemR23 was expressed on the surface of
the infiltrated cells (Figures 2P and 2Q).
Next we compared the expression of chemerin and
ChemR23 in RA and OA synovial tissues by Western blot
analysis. Expression of chemerin by RA synovium was
higher than that of OA synovium (Figure 3A). The relative
amount of chemerin protein to b-actin in RA was signifi-
cantly higher than that in OA (Figure 3B). ChemR23
expression by RA synovial tissue was also significantly
upregulated compared with OA (Figures 3C and 3D).
Expression of chemerin and ChemR23 in cultured
rheumatoid arthritis fibroblast-like synoviocytes
The expression of chemerin on cultured FLSs isolated
from the RA synovium was analyzed by ELISA. Che-
merin was produced by unstimulated FLSs, and the pro-
duction was significantly upregulated by stimulation
with TNF-a and IFN-g (P <0 . 0 5 )( F i g u r e s4 Aa n d4 B ) .
IL-1b, IL-6 and TGF-b1 did not show any effect on che-
merin production (data not shown).
ChemR23 expression on FLSs was determined by immu-
nocytochemical analysis and Western blot analysis. Dou-
ble-staining revealed that cultured FLSs expressed both
ChemR23 and vimentin (Figures 4C through 4E). The use
of a specific ChemR23 Ab also showed its expression in
RA FLSs on Western blots (Figure 4F). Stimulation with
TNF-a,I F N - g,T G F - b,I L - 1 b and IL-6 did not show any
effect on the expression of ChemR23 in RA FLSs.
Chemerin enhances IL-6, CCL2 and MMP-3 production by
fibroblast-like synoviocytes
We next evaluated the effects of chemerin on the pro-
duction of inflammatory mediators by RA FLSs. The
cells were stimulated with chemerin for 24 and 48
hours, and the concentrations of IL-6 in the culture
supernatant were measured by ELISA. After stimulation
with chemerin for 24 hours, IL-6 production from FLSs
was moderately increased, although it was not statisti-
cally significant. The incubation for 48 hours showed
significant upregulation of chemerin-induced IL-6 pro-
duction from FLSs (P< 0.05) (Figure 5A). The expres-
sion of CCL2 and MMP-3 from FLSs was also enhanced
by incubation with chemerin for 48 hours in a dose-
dependent manner (P< 0.05) (Figures 5B and 5C).
Chemerin enhances cell motility of rheumatoid arthritis
fibroblast-like synoviocytes
In the RA synovium, the migration of RA FLSs into the
cartilage and bone is considered important for pannus
development [27]. Therefore, by using a scrape motility
assay, we investigated whether chemerin could directly
alter the migratory behavior of these cells. As shown in
Figures 6A and 6B, exogenously added chemerin signifi-
cantly increased the number of cells that migrated to
the scraped area (P < 0.05). Moreover, incubation with
PTX significantly suppressed chemerin-induced FLS
motility (Figures 6A and 6B). Since PTX was previously
Figure 3 Expression of chemerin and ChemR23 in rheumatoid
arthritis and osteoarthritis synovial tissue samples. (A) Western
blots of chemerin protein expression in three rheumatoid arthritis
(RA) and four osteoarthritis (OA) synovial tissues. M, protein
molecular weight marker. (B) Relative protein expression of
chemerin to b-actin in RA and OA synovial tissues. *P < 0.05 relative
to RA synovial tissue. (C) Western blots of ChemR23 protein
expression in three RA and four OA synovial tissues. M, protein
molecular weight marker. (D) Relative expression of ChemR23
protein to b-actin. *P < 0.05 relative to RA synovial tissue.
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Page 6 of 14Figure 4 Expression of chemerin and ChemR23 by rheumatoid arthritis fibroblast-like synoviocytes. (A) and (B) Chemerin expression
stimulated by TNF-a (A) or IFN-g (B) and evaluated by ELISA using supernatants of cultured fibroblast-like synoviocytes (FLSs) isolated from
synovial tissue samples taken from rheumatoid arthritis (RA) patients (n = 4). FLSs (2 × 10
4 cells/well) were stimulated at 37°C for 48 hours with
TNF-a (0.1, 1 or 10 ng/ml) (A) or IFN-g (1, 10 or 100 ng/ml) (A). Data in (A) and (B) are presented as means (± SEM) of one of four independent
experiments analyzed in triplicate. *P < 0.05 relative to control. (C) through (E) Immunocytochemistry showing double-staining of cultured RA
FLSs with (C) vimentin (D) ChemR23 and (E) a merged image of (C) and (D). (F) Western blot of ChemR23 protein expression in RA FLSs
following TNF-a (10 ng/ml), IFN-g (100 ng/ml), transforming growth factor (TGF)-b1 (1 ng/ml), IL-1b (5 ng/ml) or IL-6 (20 ng/ml) stimulation at
37°C for 24 hours.
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+
cells by ribosylation of the ai subunits of the heterotri-
meric G protein of ChemR23 [9], our result suggested
the involvement of ChemR23 with chemerin-induced
FLS motility. We also evaluated the effect of CCL2 on
FLS migration. Incubation with CCL2 (2 or 10 nM) did
not promote cell motility of FLSs (Figure 6C).
Chemerin induces activation of ERK1/2, p38MAPK and Akt
of fibroblast-like synoviocytes
To determine the signaling pathway of chemerin-induced
stimulation of FLSs, we stimulated FLSs with 10 nM che-
merin for various time periods and performed Western
blot analysis with phospho-specific Abs against ERK1/2,
p38MAPK, JNK1/2 and Akt. Unstimulated FLSs showed
only minimal phosphorylation of ERK1/2 (at zero min-
utes), whereas a marked increase in phosphorylation was
detected after five minutes of stimulation with chemerin
(Figures 7A and 7G). Cell lysates were also examined for
chemerin-induced phosphorylation of other MAP
kinases, including p38MAPK and JNK1/2. The addition
of chemerin augmented the phosphorylation of
p38MAPK at 5 to 15 minutes compared with unstimu-
lated RA FLSs, but the level decreased at 30 minutes (Fig-
ures 7B and 7H), whereas phosphorylation of JNK1/2 was
not promoted by chemerin stimulation (Figures 7C, D, I
and 7J). Next, Akt activation, which is linked to regula-
tion of proinflammatory cytokine production by RA FLSs
Figure 5 Chemerin enhances IL-6, chemokine (C-C motif) ligand 2 and matrix metalloproteinase 3 production by rheumatoid arthritis
fibroblast-like synoviocytes. IL-6 (A), chemokine (C-C motif) ligand 2 (CCL2) (B) and matrix metalloproteinase 3 (MMP-3) (C) expression levels
were measured by ELISA using supernatants of cultured fibroblast-like synoviocytes isolated from the synovium of four patients with rheumatoid
arthritis. FLSs (4 × 10
4 cells/well) were stimulated with 2, 10 or 50 nM recombinant chemerin at 37°C for 24 and 48 hours. Data are presented as
means (± SEM) of one of four independent experiments analyzed in quadruplicate. *P < 0.05 relative to samples not treated with chemerin. ns =
not significant.
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lation of RA FLSs with 10 nM chemerin resulted in
enhanced phosphorylation of Akt, with a peak level
occurring at five minutes.
IBa is one of the regulatory proteins of NF-B, a
transcriptional factor which induces various proinflam-
matory cytokines, including TNF-a and IL-6 [29,30].
When the cells were stimulated for NF-B activation,
IBa was degraded and the amount of the protein was
decreased [31]. Therefore, we analyzed the effect of che-
merin on the degradation of IBa in FLSs to clarify
whether NF-B is involved in chemerin-induced FLS
activation. Figures 7F and 7L indicate that chemerin
does not induce IBa degradation in FLSs.
Figure 6 Chemerin promotes cell motility of rheumatoid arthritis fibroblast-like synoviocytes. (A) A scraped cell-free area was created on
a monolayer of fibroblast-like synoviocytes (FLSs). After incubation with serum-free DMEM containing chemerin (2 or 10 nM) with or without
pertussis toxin (PTX) (0.5 μg/ml), the process of two-dimensional FLS migration into the cell-free area at the center of the well was
photographed with an inverted microscope at 0 and 24 hours. Representative photographs of three separate experiments are shown (A). The
number of the cells in the scraped area was counted. Data are fold increases in the number of migrating cells at 24 hours (number of cells that
migrated after chemerin stimulation compared to the number of cells without stimulation) (B). Data are presented as means (± SEM) of one of
three independent experiments analyzed in triplicate. *P < 0.05 relative to samples not treated with chemerin. **P < 0.05 relative to samples not
treated with PTX; ns, not significant. (C) Fold increase in the number of migrating cells when FLS were stimulated with 2 or 10 nM of
chemokine (C-C motif) ligand 2 (CCL2) for 24 hours is shown; ns = not significant.
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Page 9 of 14Figure 7 Chemerin activates p44/42 mitogen-activated protein kinase, p38 mitogen-activated protein kinase and Akt in rheumatoid
arthritis fibroblast-like synoviocytes. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) were left unstimulated (zero minutes) or
stimulated with 10 nM chemerin for 5 to 30 minutes. Cell lysates were examined by Western blot analysis with anti-phospho-p44/42 mitogen-
activated protein kinase (anti-phospho-ERK1/2) and pan-ERK1/2 (A), phospho-p38 mitogen-activated protein kinase (phospho-p38MAPK) and
pan-p38MAPK (B), phospho-c-Jun N-terminal kinase (pan-JNK)1/2 and pan-c-pan-JNK1/2 (C) and (D), phospho-Akt and pan-Akt (E) and regulator
of NF-B( I Ba), and b-actin (F). Shown are band intensity (expressed in arbitrary units) of phospho-ERK1/2 (G), p38MAPK (H), JNK1 (I), JNK2 (J)
and Akt (K) normalized to pan-ERK1/2, p38MAPK, JNK1, JNK2 and Akt, respectively. Relative expression of IBa protein to b-actin is also shown
(L). The results are representative of three different experiments performed using RA FLSs from three different patients.
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Page 10 of 14Involvement of ERK1/2, p38MAPK and Akt pathways in
chemerin-induced IL-6 production and cell motility of
fibroblast-like synoviocytes
Next we examined the effects of signal blockade on IL-6
production and cell motility of FLSs to evaluate the
involvement of signal transduction in chemerin-induced
FLS activation. PD98059 (MEK, upstream of ERK1/2,
inhibitor [32]), SB203580 (p38MAPK inhibitor [33]) and
LY294002 (PI3K, upstream of Akt, inhibitor [34]) were
used to block each signaling pathway. Pretreatment with
10 μM PD98059, SB203580 and LY294002 significantly
inhibited chemerin-induced IL-6 production by RA FLSs
(P < 0.05) (Figure 8A). The chemerin-induced enhance-
ment of IL-6 production was not inhibited by polymyxin
B, suggesting the lack of a significant amount of endo-
toxin in this procedure. Furthermore, chemerin-
enhanced cell motility was inhibited by SB203580 and
LY294002, but not by PD98059 (Figures 8B and 8C).
Discussion
In this study, we have shown that chemerin and
ChemR23 are highly expressed in RA synovium. Che-
merin enhanced the production of IL-6, CCL2 and
MMP-3 from RA FLSs and promoted cell motility.
These results suggest that chemerin activates FLSs in
the RA synovium and is probably involved in the patho-
genesis of RA.
Our results show upregulation of chemerin and accu-
mulation of ChemR23
+ cells in RA synovium. We found
that chemerin was expressed on synovial lining and sub-
lining cells and on endothelial cells. Moreover, our
study shows that FLSs isolated from RA synovium also
produce chemerin in vitro and that this production is
upregulated by stimulation with TNF-a and IFN-g,
which characterize the inflammatory environment in the
RA synovium. In this regard, it was reported that the
concentration of chemerin in the synovial fluid was
much higher in RA than that in OA (358 ng/ml vs < 1
ng/ml) [9]. ChemR23 was expressed on most macro-
phages, CD1a
+ immature DCs and FLSs in RA syno-
vium. A few DC-LAMP
+ mature DCs also expressed
ChemR23. It was previously reported that ChemR23 was
expressed on immature DCs derived from peripheral
blood and that the expression was downregulated by
maturation induced by lipopolysaccharide or CD40L [9].
The unique pathway of activation of the chemerin
precursor, prochemerin, has been well-investigated
[13-15,35,36]. Prochemerin is considered to be activated
through C-terminal six- or seven-amino acid processing
by protease and to be produced by neutrophils and mast
cells at inflammatory sites. Neutrophils and mast cells
are known to release protease-rich granules and to
secrete immune mediators to activate themselves and
other immune cells, triggering positive regulatory
feedback that leads to acute or chronic RA inflammation
[37-39]. Considered together, our data suggest that che-
m e r i ni sp r o d u c e da th i g hl e v e l sb yF L S si nR As y n o -
vium and that extracellular protease is produced by
preexistent neutrophils and mast cells converted from
inactive prochemerin into bioactive chemerin, which
have powerful chemoattractant properties for migration
of macrophages and DCs into the RA synovium.
The present results reveal that the expression of
ChemR23 on RA FLSs and chemerin itself activate FLSs
to enhance the production of IL-6 and CCL2. IL-6 is
considered to have pleiotropic functions, including the
regulation of maturation and activation of T and B cells,
macrophages, osteoclasts, chondrocytes and endothelial
cells in RA [40,41]. Clinically, tocilizumab, a humanized
mAb specific for IL-6R, has outstanding anti-inflamma-
tory effects, including suppression of disease activity and
erosive progression in patients with RA that is resistant
to traditional disease-modifying antirheumatic drugs
[42]. CCL2 is known as a prototype chemokine that
attracts monocytes, T cells, NK cells and basophils into
the RA synovium [43]. Therefore, our results indicate
that chemerin may be involved in the enhancement of
local proinflammatory cytokine and chemokine produc-
tion by RA FLSs, leading to persistent amplification of
inflammation in the RA synovium, possibly in an auto-
crine or paracrine manner.
The present results indicate that chemerin enhances
the cell motility of RA FLSs, whereas CCL2 does not
promote FLS migration by this examination procedure.
These data suggest that the effect of chemerin for FLS
mobility is not affected by inducing the production of
CCL2. In the RA joints, the pannus tissue migrates and
invades the cartilage and bone, which contribute to
damaging these structures [44]. FLSs are the predomi-
nant cell type in pannus tissue, especially at the pannus-
cartilage junction [45]. FLSs retrieved from synovial tis-
sues directly cause cartilage degradation when cocul-
tured with macrophages in vitro [46], suggesting that
FLS migration and invasion play a central role in pannus
tissue-related cartilage degradation in RA. Moreover,
our results show that chemerin enhances MMP-3 pro-
duction from RA FLSs, which is a proteolytic enzyme
with cartilage degradation properties. Collectively, our
results suggest that chemerin plays an important role in
cartilage destruction through FLS activation.
The present results show that chemerin enhances the
activation of ERK1/2, p38MAPK and Akt, but not of
JNK1/2 and NF-B, in FLSs. Moreover, pretreatment
with a specific inhibitor of MEK, p38MAPK, and PI3K
suppressed chemerin-induced IL-6 production, and p38
MAPK and PI3 kinase inhibitor reduced RA FLS cell
motility. These results suggest the involvement of both
the MAPK (including MEK-ERK1/2 and p38MAPK) and
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Page 11 of 14Figure 8 Involvement of mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt pathways in chemerin-induced
fibroblast-like synoviocyte activation. (A) Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) were pretreated for 30 minutes with
PD98059 (mitogen-activated protein kinase kinase inhibitor, 10 μM), SB203580 (p38 mitogen-activated protein kinase inhibitor, 10 μM), LY294002
(phosphoinositide 3-kinase inhibitor, 10 μM), or polymyxin B (50 μg/ml) before stimulation with or without 50 nM chemerin for 48 hours. IL-6
production in the supernatant was measured by ELISA. Data are presented as means ± SEM of one of four independent experiments analyzed in
quadruplicate. LY = LY294002; PD = PD98059; polyB = polymyxin B; SB = SB203580. *P < 0.05 relative to treatment with 50 nM chemerin; ns, not
significant. (B) and (C) Effects of PD98059, SB203580 and LY294002 on FLS motility were assessed by scrape motility assay. Representative two-
dimensional photographs of FLS migratory process into the scraped cell-free area (0 and 24 hours) are shown in (B). The number of migrating
cells in the scraped area was counted. Data represent the fold increase in the number of migrating cells, shown in (C). Data are presented as
means ± SEM of one of four independent experiments analyzed in triplicate. *P < 0.05 relative to samples not treated with inhibitor; ns, not
significant.
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Page 12 of 14PI3K-Akt pathways in chemerin-induced IL-6 produc-
tion by RA FLSs. The p38MAPK and PI3K-Akt path-
ways are also involved in cell motility induced by
chemerin. Chemerin activated macrophage adhesion to
fibronectin by activation of p38MAPK and PI3K-Akt
signaling pathway [47]. These results suggest that che-
merin activates macrophages as well as FLSs in RA
synovium.
Conclusions
Our results identify the important role of chemerin in
the activation of FLSs in RA synovium, suggesting that
chemerin and ChemR23 interaction might play a role in
the pathogenesis of RA.
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